Short answer
SI-BONE, Inc. (SIBN) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $49M (up 20.6% year over year) with net income of −$5M.
Q3 2025 key financials · XBRL
- Revenue
- $49M
- +20.6% YoY · +0.1% QoQ
- Net income
- −$5M
- +30.6% YoY · +25.8% QoQ
- Operating margin
- -11.1%
- Gross margin
- 79.8%
- EPS (diluted)
- −$0.10
- +37.5% YoY · +33.3% QoQ
Source: XBRL data from the SI-BONE, Inc. (SIBN) Q3 2025 10-Q on SEC EDGAR. USD.
SI-BONE, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $48.7M, up 20.6% YoY from $40.3M, driven by higher U.S. case volumes
- Gross margin 79.8% vs 79.1% YoY, reflecting lower product costs despite higher royalties and reserves
- U.S. revenue $46.4M, up 21.2% YoY; international revenue $2.3M, up 10.2%
- Cash and marketable securities $145.7M vs $150.0M at December 31, 2024; debt unchanged at $35.5M
- No positive operating cash flow; funding expected for 12 months, with additional-capital risk from downturns and inventory needs
Risk Factors
- Newly heightened regulatory risk from federal workforce reductions and October 1, 2025 shutdown, potentially delaying FDA submissions
- Reimbursement risk from CPT 27279 definition changes effective January 1, 2026, potentially weakening coverage for existing procedures
- Supply-chain risk from titanium disruptions and potential tariffs on Canadian or other titanium, increasing implant costs
- Liquidity risk from Third Amendment Term Loan maturity on September 1, 2029, requiring refinancing or renewal
- Manufacturing risk from contract-sterilizer capacity or compliance failures, potentially delaying product availability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SI-BONE, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.